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The finding of an indeterminate adrenal mass at radiological investigations is a challenge for physicians.
Complex diagnostic work-up, periodic follow-up, or surgical intervention are therefore needed to rule out
malignant lesions. Tertiary care hospitals are provided with 18F-fludeoxyglucose (18F-FDG) positron
emission tomography (PET) and 18F-dihydroxyphenylalanine (18F-DOPA) PET, which aid in the charac-
terization of indeterminate adrenal masses. Nevertheless, the histopathological examination may be re-
quired to excludemalignancy or rare etiologies. A 54-year-oldwomanpresented to our clinic 6months after a
cerebral hemorrhage. Shewashypertensive andhad recently discovered a left adrenalmass of 15mmduring
an abdominal ultrasound. Contrast-enhanced CT, following adrenal protocol, revealed a 14-mm adrenal
mass without characteristics suggestive of an adrenal adenoma. Tumor markers were negative. Functional
tests excluded hormone hypersecretion. An 18F-DOPA PET was negative. An 18F-FDG PET showed mild
uptake of both the adrenal glands,with amore circumscribed pattern in the left one (maximumstandardized
uptake value 5 4). As the clinical diagnosis was still indeterminate, we performed laparoscopic left ad-
renalectomy. The histopathological examination described a sclerosing angiomatoid nodular transformation
(SANT) of the adrenal gland, a benign lesion already described as a rare occurrence only in the spleen. IgG4
levels were reduced. In conclusion, this is a report of a SANT of the adrenal gland, a novel entity that should
be taken into consideration in the differential diagnosis of indeterminate adrenal masses at CT scan.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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The clinical diagnosis of an incidentally discovered adrenal mass requires multiple laboratory
tests and imaging investigations [1]. Nevertheless, in certain circumstances, a definitive di-
agnosis is hard to achieve, meaning that only the histopathological examination represents the
Abbreviations: 18F-DOPA, 18F-dihydroxyphenylalanine; 18F-FDG, 18F-fludeoxyglucose; HU, Hounsfield unit; PET, positron emission
tomography; SANT, sclerosing angiomatoid nodular transformation; SUVmax, maximum standardized uptake value.
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last step in the diagnostic work-up. Multidisciplinary teams are therefore needed to identify
all of the possible differential diagnoses and decide the best treatment options.
Radiological imaging for the diagnosis of adrenal malignancy is often cumbersome and
requires an expert radiologist [2]. Tumor size, margins, and homogeneity may help in the
decision to bring the patient to surgical attention. Noncontrast CT scan appears to be highly
sensitive in the diagnosis of adrenal cancer but shows poor specificity when nonenhanced
tumor density cut-off is set at 10 Hounsfield unit (HU). Moreover, there are still limited data
on the additional diagnostic role of the evaluation of the contrast mediumwashout at CT scan
and the added value of positron emission tomography (PET) scan imaging.
Here,we report the caseof amiddle-agedwomanwhosought ourattention for anadrenalmass of
uncertain origin.Written consent for publication of this CaseReport was obtained from the patient.
1. Case Description
A. Clinical History
A 54-year-old womanwas referred to the Outpatient Clinic of the Division of Endocrinology of
the Sant’Orsola-Malpighi Hospital (Bologna, Italy) in July 2017. She had been in menopause
for 3 years. Her smoking history was negative. In 2000 and 2003, she had two pregnancies
without complications. She had a positive family history of hypertension and ischemic heart
disease by her father. In November 2016, she underwent right parietal craniotomy for the
evacuation of a hematoma as a result of intraparietal right hemorrhage with signs of sylvan
subarachnoid hemorrhage. The cerebral contrast-CT was unremarkable. Specifically, there
was no evidence of arteriovenous malformation or aneurisms of cerebral arteries. Before the
cerebrovascular accident occurred, she had been found with elevated blood pressure values
that had been under treatment with homeopathic products. During hospital admission in
2016, urinary tests showed a mild elevation of adrenaline (64 mg/day; normal range 1.7 to
22.4 mg/day), whereas noradrenaline (56.2 mg/day; normal range 12.1 to 85.5 mg/day) and
dopamine (358 mg/day; normal values,500 mg/day) were normal. The patient underwent an
abdominal ultrasound, showing a 15-mm left adrenal mass. Random aldosterone levels were
within the normal range (9.4 ng/dL; normal range 3.7 to 31.0 ng/dL). After hospital discharge,
she began antihypertensive treatment: ramipril 5mg, amlodipine 10mg, doxazosin 4mg, and
metoprolol 50 mg twice per day. Anticonvulsant therapy with lamotrigine 100 mg twice per
day was also started, as a result of an episode of seizures after the neurosurgical intervention.
On first admission to our Outpatient Clinic, the physical examination was unremarkable:
no signs of hypercortisolism nor neurologic deficits were detected. Body mass index was
21.2 kg/m2, blood pressure 130/85 mmHg, and heart rate 60 beats per minute. We
performed a contrast-CT scan with adrenal protocol, which confirmed an adrenal mass of
143 13 mm, without features resembling an adenoma (noncontrast density: 32 HU; venous-
phase density: 157HU; late-phase density: 93HU; absolute wash-out: 51%; relative wash-out
40%; Fig. 1). Morphology of the right adrenal gland was normal. Serum cortisol after a 1-mg
dexamethasone test was normal (0.9 mg/dL), as well as androgens (Table 1). Blood levels of
carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 15-3, carbo-
hydrate antigen 125, neuron-specific enolase, cytokeratin 19 fragments, a-fetoprotein, and
chromogranin A were also within the normal ranges. Upright aldosterone and renin
determination was not done as a result of the unfavorable risk/benefit ratio in the withdrawal
of the interfering antihypertensive treatment. With the consideration of the elevation of
urinary epinephrine, we performed an 18F-dihydroxyphenylalanine (18F-DOPA) PET scan,
which did not detect abnormalities. A CT scan was repeated 6 months later, showing the
stability of the adrenal mass size. An 18F-fludeoxyglucose (18F-FDG) PET scan revealed a
diffuse hyperfixation of both adrenal glands (Fig. 1), with amore circumscribed pattern in the
left one [maximum standardized uptake value (SUVmax) adrenal/liver 5 4:2.4].
The case was discussed in our Multidisciplinary Adrenal Team meeting. We decided for
surgical removal of such an undetermined adrenal mass. In March 2018, the patient
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Figure 1. Radiological and nuclear imaging. (A–D) CT scan. Lesion of the medial limb of
the left adrenal gland (dimension 13 3 14 mm). The region of interest for the assessment of
the density was placed over two-thirds of the surface area of the mass in the axial view. The
attenuation value assessment shows a density of (A) 32 HU on unenhanced CT, (C) 157 HU
in the venous phase (at 70 to 80 seconds), and (D) 93 HU in the delayed phase (at 15
minutes) with absolute wash-out of 51% and relative wash-out of 40%. (E and F) 18F-
Fludeoxyglucose (18F-FDG) PET scan: diffuse hyperfixation of both adrenal glands, with a
doi: 10.1210/js.2019-00013 | Journal of the Endocrine Society | 1209
underwent laparoscopic left adrenalectomy without complications. The histopathological
examination showed a solid, white-tan mass (0.8 cm maximum diameter; (Fig. 2). The
nodular lesion was predominantly constituted by fibrosclerotic stroma with hemosider-
ophages, fibroblasts, and lymphomononuclear cells. The lesion showed a storiform growth
with relatively sharp demarcation and was composed of epithelioid cells arranged in strands
with a storiform pattern. The cells often showed a histiocytoid appearance; the nuclei were
commonly vesicular without distinct nucleoli. Mild nuclear atypia was only focally observed.
Mitoses were absent. Furthermore, the cells showed an abundant hyaline cytoplasm with
variable intracytoplasmic vacuoles, and some elements presented lumina occluded by hyaline
thrombi. A dense hyaline stroma was diffusely present. Necrosis and calcification were not
observed. The lesion was composed of cells that were diffusely positive for CD34, factor XIIIa,
and Friend leukemia integration 1 with a focal expression of CD31, indicating derivation
from sinusoidal, capillary-like, and vein-like elements. The CD34-immunonegative cells were
stained for CD68 (sparse histiocytes). Expression of adrenal markers (inhibin, synapto-
physin, Melan A, GATA-3) and all types of cytokeratins, including epithelial membrane
antigen, were performed and resulted negative. S-100, D-240, signal transducer and activator
of transcription 6, humanmelanoma black 45, calretinin, anaplastic lymphoma kinase 1, and
IgG4 were negative. CD3, CD4, and CD8 highlighted sparse T-lymphocytes, mostly CD8
positive. The Ki-67 proliferative index was ,1%. The rest of the adrenal gland had a
preserved architecture.
more circumscribed pattern in the left one [maximum standardized uptake value (SUVmax)
adrenal/liver 5 4:2.4]. The white arrow indicates the left adrenal gland. (G and H) 18F-
Dihydroxyphenylalanine (18F-DOPA) PET showing no uptake from the adrenal glands. The
yellow arrow indicates the left adrenal gland.
Table 1. Biochemical, Hormonal, and Radiological Characteristics
Characteristics
Laboratory values
Sodium, mM 143
Potassium, mM 4.5
Aldosterone, ng/dL 9.4
ACTH, pg/mL 20
Cortisol, ng/mL 160
1 mg-DST cortisol, mg/dL 0.9
Testosterone, ng/mL 0.33
Dehydroepiandrosterone sulfate, mg/dL 119
Dehydroepiandrosterone, ng/mL 6.1
Androstenedione, ng/dL 298
17-Hydroxyprogesterone, ng/dL 76
TSH, mU/mL 1.98
Free thyroxine, pg/mL 9.6
IgG4, mg/dL (normal range 39.2 to 86.4) 17.4
Imaging findings
CT Basal, HU 32
CT Venous phase, HU 157
CT Late phase, 15 min, HU 93
CT Absolute wash-out, % 51
CT Relative wash-out, % 40
18F-FDG PET: SUVmax left adrenal gland 4.0
18F-FDG PET: SUVmax right adrenal gland 4.0
18F-FDG PET: SUVmax liver 2.4
18F-DOPA PET Negative
Abbreviations: ACTH, adrenocorticotrophic hormone; DST, dexamethasone; TSH, thyrotropin hormone.
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Figure 2. (A) Gross appearance of the adrenal gland with a nodule of 0.8 cm. (B and C) The
lesion appeared nodular and predominantly fibrosclerotic: (B) hematoxylin and eosin; (C)
Weigert -von Gieson, 310. (D and E) Epithelioid cells arranged in strands with a storiform
pattern, with vesicular nuclei and intracytoplasmic vacuoles (hematoxylin and eosin, 350,
3200). (F) Abundant collagenized stroma (Weigert -von Gieson, 3100). (G) Diffuse CD34
expression (3200).
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The microscopic appearance of the lesion and the protein expression pattern resembled
that of the sclerosing angiomatoid nodular transformation (SANT), a rare pathological
finding that has been described in the spleen in a few Case Reports worldwide so far [3–6].
Splenectomy is the treatment of choice for the management of splenic SANT. Patients have a
good prognosis with no recurrence. The pathogenesis is still unclear. It has been proposed
that SANT may represent a splenic hamartoma undergoing an unusual form of sclerosis, a
peculiar reactionary transformation of red pulp, as a result of an exaggerated stromal re-
sponse [4]. It appears that SANT is probably a reactive lesion rather than a true neoplastic
process, a theory supported by the high prevalence of concurrent conditions in SANT pa-
tients. Recently, a number of authors have suggested that the proliferation seen in SANTmay
be associated with IgG4-related sclerosing lesions as a result of the presence of plasma cells
found in its stroma [6]. The splenic lesion is commonly described in middle-aged adults after
being found incidentally on radiographic imaging [4].
With the consideration that such a lesion has been found in the context of IgG4-related
disease, we measured circulating IgG4 levels in our patient, which were under the lower
reference range (17.4 mg/dL; normal range 39.2 to 86.4 mg/dL). Ten months after surgery, at
last follow-up, the physical examination of the patient was unremarkable. Currently, our
report represents a description of SANT outside of the spleen, and with the consideration of
the benign appearance, such as the negativity for IgG4, we may speculate that the described
lesion could represent an incidental hamartoma or a reactive process.
2. Conclusion
This Case Report describes a case of SANT reported in the adrenal gland. The clinical and
the radiological characteristics of this entity are not specific, except for a radiological ap-
pearance of a nonadenomatous lesion at abdominal CT-scan. The role of the 18F-FDG PET
scan is uncertain, even though a mild uptake may be detected, as previously reported in
spleen lesions [5]. Therefore, adrenal malignancy and pheochromocytoma should be con-
sidered in the differential diagnosis of this condition, which can be diagnosed only after
histopathological examination.
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